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EFFICACY OF SURGICAL AND MEDICAL INTERVENTION 
FOR TREATMENT OF LEFT-SIDED ENDOCARDITIS 
STERGIOS GATZOFLIAS 
ABSTRACT 
 Background 
Treatment of left-sided Infective Endocarditis (IE) is challenging due to the 
presence of both surgical and medical interventions. The choice typically depends on the 
patient’s surgical risk and severity of infection. Our aim is to compare outcomes of IE 
patients who undergo valve replacement surgery with patients who are treated with solely 
antibiotics.  
Methods 
Patients undergoing valve surgery at our institution from 1995 to 2014 (n=196) 
and patients who were treated medically for IE from 2001 to 2014 (n=120) were included 
in this study. In total, 316 patients were included and clinical data was retrospectively 
collected from chart review. Society of Thoracic Surgeons (STS) Scores were calculated 
to assess for surgical risk and data for preoperative fever, angina, and abscess was 
collected to assess for severity of infection. The primary outcome of interest was 
mortality at 30 days and 1 year post-treatment and secondary outcomes included post-
treatment development of septic shock, MI, embolic events, recurrence of infection, 
stroke, and renal dysfunction. Cox regression analyses were performed to assess the 
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likelihood of mortality based on the patient’s pre-intervention comorbidities and 
characteristics. A Kaplan-Meier Analysis was also conducted to assess for survival at 
both 30 days and 1 year. 
 Results 
 Pre-operative fever (68.88% surgical vs 52.50% medical, p=0.002), angina 
(13.78% surgical vs 2.50% medical, p<0.05), and presence of abscess (33.37% surgical 
vs 6.67% medical, p<0.05) were significantly higher in the surgical population. Mortality 
at both 30-days (7.65% surgical vs 29.17% medical, p<0.05) and 1 year (17.35% surgical 
vs 46.67% medical, p<0.05) was significantly higher in the medical cohort. Mortality in 
patients presenting with valvular abscess was significantly higher in the surgical 
population at 30 days (4.5% surgical vs 62.5% medical, p<0.05) and 1 year (15.15% 
surgical vs. 75.00% medical, p<0.05). Surgical risk was significantly higher in medical 
patients overall (p<0.05), but not significantly higher in the pathogen specific subgroups. 
By individual pathogen, medical mortality was significantly higher at both 30 days and 1 
year in the MRSA (p=0.0004 and p=0.0002) and Staphylococcus population (p=0.001 
and p=0.0005) but only significantly higher in the Streptococcus population at 1 year 
(p=0.032).    
 Conclusion 
 Valve Replacement Surgery in patients with left-sided MRSA and non-MRSA 
Staphylococcus IE leads to significantly better mortality outcomes at 30 days and 1 year 
than medical management. Specifically, we suggest that patients with preoperative 
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valvular abscess undergo valve replacement surgery, regardless of pathogen, and that 
patients with MRSA and non-MRSA Staphylococcus IE be strongly considered for 
surgical intervention.  
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INTRODUCTION 
 
 Infective Endocarditis (IE) is a microbial infection of the inner lining of the heart, 
the endocardium. IE is typically caused by bacteria that travel through the blood and 
settle on the heart valves. IE is a very rare disease that affects less than 1% of the 
population, but once contracted, it holds a 1-year mortality rate of 40% (Kiefer et al., 
2011).   
The presence of bacteria in the blood is called bacteremia. Once bacteria has 
entered the bloodstream, there is potential for bacteria to deposit on any one of the 
cardiac valves and form a bacterial vegetation. Bacteria can enter the body during a 
surgery, a dental procedure, or by the use of contaminated needles when injecting IV 
drugs. Although blood is constantly flowing through the cardiac valves, they do not 
receive a devoted blood supply, which makes it very difficult for the body’s immune 
system to combat a bacterial vegetation. This risk of bacterial deposition greatly increases 
if the patient’s cardiac valve is already damaged, such as a patient presenting with a 
bicuspid aortic valve or a mitral valve prolapse (Vallejo, 2016).  
Cardiac Anatomy 
The heart consists of a series of chambers that synergistically work to pump blood 
throughout the body and the lungs. It consists of two smaller chambers called atria and 
two larger chambers called ventricles. Deoxygenated blood enters into the right atrium 
via the vena cava and passes through the tricuspid valve into the right ventricle. The right 
side of the heart deals solely with deoxygenated blood returning from the periphery and 
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pumps this blood into the pulmonary system through the pulmonary valve to become 
oxygenated. The oxygenated blood returns to the left atrium via the four pulmonary veins 
and is pumped through the mitral valve into the left ventricle. Finally, the blood is 
pumped up through the aortic valve into the aorta and to the rest of body.  
The four cardiac valves play a major role in the proper movement and pumping of 
blood in this system. They act as one-way conduits that prevent the backflow of blood 
into the previous chamber. Valves are thin pieces of endocardium that consist of either 
two or three distinct leaflets. They are rooted tightly in the annulus fibrosus and are 
tethered to the cardiac skeleton so that they maintain their position.  
 
 
 
 
 
 
 
Figure 1: Transverse Section of Heart. This transverse section of the heart highlights 
the four cardiac valves and their position in the heart.  It denotes the varying number of 
leaflets and the way the valves are seated in the cardiac anatomy. Figure taken from 
Teachmeanatomy.info  
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The two atrio-ventricular (AV) valves are the mitral and tricuspid valves and as 
their name implies, separate the atria from the ventricles. The AV valves are attached to 
papillary muscles in the right and left ventricles via chordae tendinae that aid them in 
their proper functioning. The chordae tendinae and papillary muscles ensure that the 
valves close properly and do not protrude, or prolapse, into the atria. During ventricular 
diastole, the pressure in the atria surpasses the pressure in the ventricles and this pressure 
pushes open the valves to allow blood to flow into the ventricles. Once the blood has 
entered the ventricles, the valves close to prevent any backflow. The closure of the AV 
valves is noted as the first heart sound, commonly referred to as the “lub”.  
Once blood has entered the ventricles, focus shifts to the aortic and pulmonary 
valves, which are known as semilunar valves. These two valves do not have any chordae 
tendinae or papillary muscle attachments and open and close solely based on pressure 
changes in the heart. Pressure begins to rise in the ventricles and once that pressure 
eclipses the pressure in the aorta or pulmonary artery, the semilunar valves open and the 
ventricles contract, propelling blood to the body or pulmonary system. The closure of the 
semilunar valves is noted as the second heart sound, commonly referred to as the “dub”. 
The tricuspid, pulmonary, and aortic valve all contain three leaflets are referred to 
as tricuspid valves while the mitral valve contains only two leaflets and is referred to as 
the bicuspid valve. The differences in pressure are important to the location of the 
bacterial vegetation in IE and will be discussed in detail in another section.  
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Valvular Pathology 
The cardiac valves are all susceptible to disease. The most common valvular 
pathologies are stenosis and regurgitation/insufficiency. Stenosis is the narrowing of the 
valves due to the accumulation of calcification on the leaflets. This is typically an age-
related process and can cause angina, syncope, or congestive heart failure (Rogers, 2013). 
Regurgitation/insufficiency is the backflow or leaking of blood into the prior cardiac 
chamber. This is also an age-related process but is commonly attributed to the dilation of 
annulus fibrosis that prohibits the valves to closing properly (Maurer, 2006). The 
presence of any of these pathologies facilitates the formation of a bacterial vegetation on 
the cardiac valves.  
Figure 2: Mitral Valve Stenosis and Regurgitation. These images represent stenosis 
and regurgitation of the mitral valve. Mitral valve stenosis depicts the blood having a 
difficult time entering the left ventricle from the left atrium. Mitral valve regurgitation 
highlights the backflow of blood from the left ventricle to the left atrium. Figure taken 
from heartsurgeryinfo.com   
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Classifications of IE 
IE is mainly classified as native or prosthetic IE. This classification aids in 
determining how the infection was acquired and determines how IE should be treated. 
Prosthetic valve endocarditis can be further broken down into early and late endocarditis. 
Early prosthetic valve endocarditis is defined as infection contracted less than 1 year 
from the operation and late prosthetic valve endocarditis is contracted more than 1 year 
post-op (Nonaka et al., 2013). Early prosthetic valve endocarditis is associated with a 
higher rate of heart failure and mortality and patients should be monitored closely post-op 
to avoid the development of early prosthetic valve IE (Castillo et al., 2004). The type of 
prosthetic valve that patients receive also impacts the risk of acquiring IE post op, as 
mechanical valves have a significantly higher rate of endocarditis at 1 year than 
bioprosthetic valves (Lund & Bland, 2006). Additionally, it is also important to 
determine if a patient has contracted right or left sided endocarditis. Right sided 
endocarditis is limited to tricuspid and pulmonic valve infection and left sided 
endocarditis includes the mitral and aortic valve. Patients who have left sided 
endocarditis have significantly worse preoperative conditions and also worse clinical 
outcomes post-operatively (Kamaledeen, Young, & Attia, 2012; Musci et al., 2007). 
Furthermore, IE used to be subdivided into acute and subacute classifications. These 
classifications attempted to reflect the severity and progression of the IE. Subacute IE 
was defined as a milder strain of infection and acute IE was characterized as more 
volatile and severe. Presently, this classification is not used due to its inaccuracy in the 
clinical setting (Morris, 2006). Physicians now prefer to use the terms short and long 
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incubation when characterizing IE, with short incubation signifying an infection of less 
than six weeks and long incubation signifying an infection of more than six weeks 
(Morris, 2006). The final classification of IE that is used clinically is characterizing the 
infection by pathogen. This system is valuable to physicians as they seek to treat IE 
because it is paramount to identify the invading pathogen to best treat the infection. The 
pathogen is confirmed via a blood culture test and the therapeutic course is then 
discussed. The most common pathogens found in IE are Streptococcus and 
Staphylococcus (Mostaghim, Lo, & Khardori, 2017).  Staphylococcus IE is associated 
with a more severe preoperative presentation that non Staphylococcus IE (Han et al., 
2017; Miro et al., 2005).     
 Risk Factors, Pathogenesis, and Symptoms of IE 
The chance of contracting IE increases with several key risk factors. Congenital 
heart defects, rheumatic heart disease, and valve diseases are all contributors to the 
development of IE. Congenital heart defects, such as a bicuspid aortic valve and patent 
ductus arteriosus, are responsible for approximately 15% of all IE cases (Braunwald & 
Bonow, 2012). Studies have also shown that approximately 5% of patients with 
Rheumatic Heart Disease (RHD) develop IE (Okello et al., 2013). RHD, which is damage 
to the cardiac valves, develops after a patient is diagnosed with rheumatic fever and is 
typically treated with valve replacement surgery. If a patient does not have a congenital 
heart defect or was diagnosed with rheumatic fever earlier in life and they develop 
valvular regurgitation or stenosis, they are diagnosed with valve disease and are also 
susceptible to the development of IE. The diseased valves facilitate the attachment of 
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bacteria due to the presence of a non-bacterial thrombus (NBT). Once a patient presents 
with left-sided (aortic and mitral) regurgitation, there is endocardial damage that occurs 
at the site of both of these valves. This endocardial damage attracts platelets and fibrin to 
the site which form a clot, called NBT, and is the location to which bacteria can deposit if 
they enter the bloodstream. The NBT forms on the side of the valve that is exposed to 
lower pressure due to the Venturi Effect, which states that in a narrow space, fluid 
pressure decreases with a higher velocity. This principle pushes the NBT to the valvular 
chamber with lower pressure. In mitral valve endocarditis, the vegetation will develop on 
the atrial side of the mitral valve since that atrium has a lower pressure than the ventricle. 
In aortic valve endocarditis, the vegetation will develop on the ventricular side of the 
aortic valve since the left ventricle has a lower pressure than the aorta.  
 
 
 
 
 
 
 
 
Figure 3: Location of Vegetations on the Cardiac Valves. This image represents the 
location of the IE on the four cardiac valves. All of the vegetations depicted are situated 
on the lower pressure side of the two chambers in question. As discussed above, the left 
atrium has a lower pressure than the left ventricle and therefore the IE develops on the 
atrial side. Figure taken from merckmanuals.com   
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If a patient who has a valve disease with a NBT is exposed to bacteria that enters 
their bloodstream, there is potential for that bacteria to attach onto the NBT and form a 
bacterial vegetation. The bacteria colonizes the NBT and the patient contracts IE and 
presents with numerous systems that aid in the diagnosis of IE. 
     
 
Figure 4: Transesophageal Echocardiogram (TEE) of Mitral Valve Endocarditis. 
This TEE depicts the location of a vegetation on the mitral valve. This vegetation is 
located on the atrial side of the valve and is pushed to the side of the valvular opening, 
away from the center.  This is consistent with the principles described in the Venturi 
Effect. Figure taken from sciencedirect.com   
 
Patients with IE present with a myriad of symptoms. Fever, fatigue, and the 
development of a new cardiac arrhythmia are common (Vallejo, 2016). Angina, shortness 
of breath, and the heart failure have also been observed (Mostaghim et al., 2017). Since 
the cardiac valves constantly open and close, there is a high risk that a piece of bacteria 
can detach from a vegetation and embolize. This is very dangerous as this embolus can 
 9 
cause an infarct if it lodges in a major blood vessel of organ. Left-sided vegetations 
typically embolize to the spleen, kidney, or the brain and can cause a stroke or severe 
organ failure (Ferro & Fonseca, 2014). Furthermore, Janeway lesions, 
glomerulonephritis, Osler nodes, and Roth spots have been seen in patients with IE. 
Janeway lesions are erythematous lesions that appear on your palms and your feet 
(Divakaramenon, 2005). They arise due to chronic bacterial infection and are hallmarks 
in the presentation of IE. Glomerulonephritis is a disease of the kidney that affects the 
kidney’s filtration ability. Glomerulonephritis develops as a result of an embolus from a 
bacterial vegetation that lodges in the kidney (Boils, Nasr, Walker, Couser, & Larsen, 
2015). It can cause short term necrosis and if the damage is serious and prolonged, can 
lead to chronic kidney disease (Boils et al., 2015). Osler nodes, similar to Janeway 
lesions, are lesions that develop on the palms and feet due to increased immunological 
activity. They differentiate themselves from Janeway lesions in that they are considered 
to be tender to the touch, while the Janeway lesions are not (Farrior & Silverman, 1976). 
Finally, Roth spots are white centered retinal hemorrhages that present due to increased 
immune activity (Mahroo & Graham, 2014).   
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Figure 5: Clinical Manifestations of Infective Endocarditis. This image represents the 
clinical manifestations of the IE. The impact of this infection is not limited to the 
cardiovascular system and has wide reaching effects. All of these symptoms and 
presentations aid physicians in diagnosing IE. Figure taken from slideshare.net   
 
Diagnosis of IE 
The presence of the aforementioned symptoms as well as a thorough patient 
history allows practitioners to suspect the presence of IE. This diagnosis can be 
confirmed by meeting the criteria set out in the Modified Duke Criteria for Endocarditis. 
When using the Duke Criteria, there are three attainable results: rejected endocarditis, 
possible endocarditis, and definite endocarditis. These results depend on how many of the 
criteria the patient meets. The criteria are split into definitive pathological criteria, major 
criteria, and minor criteria. There are two definitive pathological criteria where if either 
of them are met, the diagnosis of IE is confirmed. The first pathological criteria is if a 
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specimen of the vegetation has been cultured and returns positive for bacteria, the 
diagnosis is confirmed. The second pathological criteria is if the vegetation or the abscess 
due to the vegetation is confirmed histologically to show active IE, the diagnosis is 
confirmed. If neither of these above pathological criteria are met, to confirm the 
diagnosis of IE would require a combination of two major criteria, one major and three 
minor criteria, or five minor criteria. In total, there are two major and five minor criteria. 
The two major criteria are the presence of endocardial involvement and a blood culture 
positive for IE. Endocardial involvement can include the presence of an abscess, the 
dehiscence of a prosthetic valve, or the presence of a mass on the valve that is confirmed 
by TEE of Transthoracic Echocardiogram (TTE). To have a blood culture positive for IE, 
there needs to have been two blood cultures drawn approximately 12 hours apart that 
both return positive for IE. If both of these major criteria are met, then your diagnosis of 
IE is confirmed. If none or only one of the criteria are met, you must move on to the 
minor criteria to confirm your diagnosis. The five minor criteria are: the presence of 
fever, a preexisting heart condition or intravenous drug use, the presence of vascular 
phenomena, the presence of specific immunological phenomena, and microbiological 
evidence. The presence of emboli, infarcts, or Janeway lesions, discussed above, fit into 
the domain of vascular phenomena. Roth spots, Osler nodes, or glomerulonephritis are 
examples of immunological phenomena that the Duke Criteria accept as a minor criteria. 
Finally, any microbiological evidence, such as only one positive blood culture, is 
sufficient to be considered as a minor criteria (L. M. Baddour, 2005; Durack, Lukes, & 
Bright, 1994; Li et al., 2000; Thuny, 2005).  
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Studies have been conducted that attempted to use serum biomarkers in order to 
predict outcomes for patients with IE. Biomarkers such as B-type natriuretic peptide 
(BNP), troponins, procalcitonin, and cystatin C have provided a foundation as a group of 
biomarkers that can potentially be used to determine a prognostic survival rate for 
patients diagnosed with IE. More research on these biomarkers needs to be conducted in 
order to introduce a reliable and accurate system for predicting the course of IE (Gucuk 
Ipek et al., 2015; Purcell et al., 2008; Shiue et al., 2010; Siciliano et al., 2014; Snipsøyr, 
Ludvigsen, Petersen, Wiggers, & Honoré, 2016)  
Treatment of IE 
With the diagnosis of IE comes a challenge: determining whether to treat the 
patient solely with antibiotics or a combination of antibiotics and surgery, most 
commonly valve replacement. This decision depends on many factors including the 
severity of infection, the risk of surgery, and the type of pathogen that has colonized the 
valve. Surgical intervention has shown to have positive outcomes in IE cases, but there is 
still debate about when to subject patients to a cardiac operation (Vikram, Buenconsejo, 
Hasbun, & Quagliarello, 2003). The location and size of the vegetation has played a 
major role in determining whether surgery or antibiotic therapy is recommended. Patients 
with mobile, large vegetations (>10mm) are more likely to develop emboli from the 
infection and should be operated on more urgently than patients with small, sessile 
vegetations (Tornos et al., 2005). Early surgery is also recommended for patients with 
preoperative cerebral emboli (Sorabella et al., 2015). The typical approach is to wait four 
weeks after the diagnosis of a septic brain embolus to allow for healing of the infarcted 
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tissue, but surgery less than 4 weeks after this diagnosis has not shown any significantly 
worse post-operative outcomes (Sorabella et al., 2015).  
Traditionally, antibiotics are started immediately following the diagnosis of IE 
(Habib, 2006). Then, if surgery is indicated, the patient will begin preparation for a valve 
replacement surgery. The duration of antibiotic therapy before surgery is questioned, but 
there have been studies that state that the duration of antibiotic therapy before surgery has 
no effect on perioperative mortality or recurrence of IE (Chastre & Trouillet, 1995; 
d’Udekem, David, Feindel, Armstrong, & Sun, 1997; Delahaye, 2004; Olaison & 
Pettersson, 2002). If surgery is indicated, the procedure will replace the native valve with 
a prosthetic valve and the surgeon will ensure that the valve area is debrided of the 
infection. Common indications for surgery include presence of valvular abscess, valve 
dehiscence, severe valvular stenosis or regurgitation, and failure of initial antibiotic 
therapy (Anantha Narayanan et al., 2016).  
The antibiotic therapy prescribed in IE depends on the type of pathogen that is 
present. The bacterial vegetation will consist of platelets, fibrin and bacteria that are 
attached to the valve which requires the therapy to contain a bactericidal element that can 
break through this material, regardless of the pathogen (Hoen, 2006). The antibiotics are 
most commonly administered intravenously for a period of four to six weeks to ensure 
that the patient receives the proper dosage. A Peripherally Inserted Central Catheter 
(PICC) can also be placed to facilitate the administration of the medication.  
For native or prosthetic streptococcal IE, penicillin G and gentamicin are used in 
combination for a duration of four to six weeks (Hoen, 2006). Penicillin serves as the 
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antibacterial medication that will combat the infection and gentamicin serves as an 
aminoglycoside which inhibits protein synthesis (Graham, 2002; Öbrink-Hansen et al., 
2017) . This combination is recommended to be followed for four weeks and the 
recommended dosage is 10-20 million units a day of penicillin G and 5-6mg/kg/day of 
gentamicin (Hoen, 2006; Öbrink-Hansen et al., 2017). In complicated cases of IE or in 
situations where the streptococci are resistant to penicillin, ceftriaxone, ampicillin, and 
amoxicillin can be used as substitutes.   
For native valve staphylococcal IE that is oxacillin susceptible, 150mg/kg/day of 
oxacillin should be prescribed with gentamicin. This combination should be used together 
for approximately the first four days and then the oxacillin should be used alone for four 
to six weeks. If the staphylococcus is resistant to oxacillin, vancomycin is prescribed as 
an alternative. For prosthetic valve staphylococcal IE, a triple combination of 
vancomycin, rifampicin, and gentamicin is recommended (Larry M. Baddour et al., 2015; 
Hoen, 2006).  
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SPECIFIC AIMS 
 
The purpose of this study is to analyze if surgical treatment of left-sided IE is 
associated with significantly lower perioperative (30 day) and 1 year post-operative 
outcomes compared to medical management after assessing for surgical risk and severity 
of pre-treatment infection. This study aims to determine the effect that various pathogens 
have on these outcomes and whether surgery should be considered earlier and more 
frequently in treatment of IE. Studies have shown that the duration of antibiotic therapy 
before surgery has no effect on perioperative mortality or recurrence of IE (Chastre & 
Trouillet, 1995; d’Udekem et al., 1997; Delahaye, 2004; Olaison & Pettersson, 2002) . 
Additionally, in patients with preoperative septic cerebral emboli, early operation for IE 
is not associated with significantly worse postoperative outcomes (Sorabella et al., 2015). 
These studies offer potential that surgical intervention may be more effective and can be 
used independently of traditional antibiotic therapy for treatment of IE. There has been no 
study that has examined surgically and medically treated patients with IE to determine 
which cohort of patients fared better at 30 days and 1 year post-treatment. This study will 
identify patients who have been diagnosed with left-sided valvular IE who have been 
treated medically and compare them to patients who underwent left-sided valve 
replacement surgery for IE.   
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METHODS 
 
 This is unpublished data and it is confidential. It is unfinalized. 
We conducted a retrospective analysis of all patients diagnosed with IE at our 
institution, New York Presbyterian Hospital and Columbia University Medical Center, 
from April 1995 to December 2014. One thousand two hundred and ten (1210) patients 
were included in this initial analysis. These patients were then checked to ensure the 
fulfillment of the diagnosis of IE according to the Modified Duke Criteria. Any patient 
with possible IE or persistent bacteremia was excluded from the study. Next, the patients 
were stratified by infecting pathogen and three cohorts were created: one for Methicillin-
Resistant Staphylococcus Aureus (MRSA), one for non-MRSA Staphylococci, and one 
for Streptococci. The three pathogens were selected due to their prevalence in the IE 
population. Within the three pathogen cohorts, another division was made that separated 
these patients into those managed medically for IE and those treated surgically. The 
medically managed cohort included patients who were treated with antibiotics for IE and 
the surgical cohort included patients who underwent valve replacement to treat their IE. 
These surgically and medically managed cohorts were used to determine which treatment 
method lead to superior perioperative and 1-year outcomes.  
 To assist with the comparison between the medical and surgical cohorts, Society 
of Thoracic Surgeon (STS) Scores for mortality were calculated for both groups. For the 
medical cohort, the “date of operation” was considered to be the date of initial definitive 
IE diagnosis and that was the date that was used to determine the 30 day and 1 year 
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window for post-treatment outcomes. Initial definitive IE diagnosis was defined as the 
first day when the patient exhibited a vegetation on a TTE or TEE and had positive blood 
cultures for an invading pathogen. Antibiotic therapy for possible IE may have been 
started prophylactically before definitive diagnosis but valvular surgery would not have 
been considered until there was the presence of a distinct vegetation and positive blood 
cultures. 
 
 
Figure 6: Breakdown of Included Patients. This image represents the amount of 
patients included in the data analysis portion of this study. It represents the breakdown 
and ultimate stratification of the variables that were included to determine if surgical 
treatment of IE is superior to medical management of IE. 
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Figure 6: Breakdown of Included Patients. This image represents the amount of 
patients included in the data an lysis portion of this study. It represents the breakdown 
and ultimate stratification of the variables that were included to determine if surgical 
treatment of IE is superior to medical management of IE.      
INITIAL IE PATIENT POPULATION (n=1210) 
MRSA (n=56) NON-MRSA STAPHYLOCOCCI (n=149) STREPTOCOCCI (n=111) 
SURGICAL (n=21) SURGICAL (n=108) MEDICAL (n=44) MEDICAL (n=35) MEDICAL (n=41) SURGICAL (n=67) 
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Figure 7: Breakdown of Pathogens. This figure represents the most common pathogens 
found in our initial analysis of 1210 patients. This was the basis for selectively examining 
the outcomes of patients with Staphylococcus, Streptococcus, and MRSA IE.     Figure 7 represents the breakdown of the most common pathogens found in our 
institutions internal databases. Of the 1210 patients, 416 (34.38%) presented with 
Staphylococcus IE, 242 (20.00%) presented with Streptococcus IE, and 142 (11.74%) 
presented with MRSA IE. Because these three pathogens were the most prevalent in the 
population, we decided to examine left sided IE in patients with only these three bacteria. 
The total number of final patients that we used in our analysis is lower than the numbers 
represented above because the above numbers are patients with positive Staphylococcus 
blood cultures. They did not all satisfy the Duke Criteria for IE and were therefore 
excluded.       Variables included in the pre-operative characteristic section included basic 
demographic information, hypertension, diabetes mellitus (DM), congestive heart failure 
(CHF), cerebral vascular accident (CVA), end stage renal disease (ESRD), chronic 
Pathogen Number of Patients Percentage of Patients 
Staphylococcus 416 34.38% 
Streptococcus 242 20.00% 
MRSA 142 11.74% 
Enterococcus 93 7.69% 
Candida 15 1.24% 
Kliebsella 14 1.16% 
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obstructive pulmonary disease (COPD), prior cardiac surgery, and arrhythmias. Data 
regarding the affected valve were collected as well. To determine severity of infection, 
data for fever, angina, and the presence of a valvular abscess were collected. 
Furthermore, all additional variables needed for calculation of STS Scores were collected 
and used in those calculations. If a patient was undergoing a procedure involving both a 
mitral valve replacement (MVR) and aortic valve replacement (AVR), the STS score for 
the AVR was used. If a patient underwent an aortic root replacement (ARR), the STS 
scores for an AVR were used.  
 Variables collected at for post-treatment outcomes at 30 days and 1 year were 
mortality, prosthetic valve dysfunction, septic shock, stroke, myocardial infarction (MI), 
embolic events, ESRD, and infection. All data were collected retrospectively from 
electronic medical records.  
 To determine significance between the medical and surgical cohorts, T-tests were 
run to determine the p values. P values less than 0.05 were considered statistically 
significant.  
 A Cox Regression analysis was also performed to control for pre-therapy 
comorbidities and demographics and predict the likelihood of mortality based on the 
patient’s preoperative patient characteristics. Hazard ratios and 95% confidence intervals 
were used to determine the direction and significance of each of the comorbidities. 
Variables used for the Cox regression were sex, age, prior cardiac surgery, CHF, HTN, 
CHF, DM, CVA, MI, AFIB, ESRD, COPD, STS score, Abscess, Fever, and Angina. 4 
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regressions were run to determine the hazard ratios for 30 day and 1 year mortality for 
both the surgical and medical cohort.  
 Finally, a Kaplan Meier Analysis was conducted to graph the survival of the 
surgical and medical patients at both 30 days and 1 year. This visual representation of the 
mortality rates of this study will confirm the significance in mortality, if any, between the 
cohorts. 
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RESULTS  
 Surgical patient data is reflected in Figure 8. One hundred ninety six (196) 
surgical patients were identified and their mean age was 58.07. One hundred twenty six 
(126) patients (63.64%) were males and seventy one (70) patients were females 
(36.36%). 49.49% of patients are White, 10.71% are Hispanic or Latino, 10.20 % are 
African American, and 38.78% are unknown. Sixty seven (67) patients had prior cardiac 
surgery and fifty one (51) presented with prosthetic valve endocarditis. 55.1% of the 
surgical patients had Staphylococcus IE, 34.18% presented with Streptococcus IE, and 
10.7% presented with MRSA IE.    
 Medical patient data is presented in Table 9. One hundred and twenty (120) 
patients treated medically for IE were identified. Sixty seven (67) patients (55.83%) are 
male and fifty three (53) patients (45.45%) are female. 45.45% of patients are White, 
14.05% are African American, 38.85% are unknown and 22.31% are Hispanic or Latino. 
Thirty four (34) patients had prior cardiac surgery and twenty one (21) presented with 
prosthetic valve endocarditis. 34.16% of the medical patients had Staphylococcus IE, 
36.67% presented with Streptococcus IE, and 29.16% presented with MRSA IE.    
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SURGICAL Overall (n=196) Staph (n=108) MRSA(n=21) Strep(n=67) 
Age 58.07 58.67 61.03 56.19 
Male, n (%) 126 (63.64) 63 (58.33) 15 (71.43) 48 (71.64) 
Female, n (%) 70 (36.36) 45 (41.67) 6 (28.57) 19 (28.36) 
White, n (%) 97 (49.49) 42 (38.89) 12 (57.14) 43 (64.18) 
Unknown, n (%)  76 (38.78) 49 (45.37) 7 (34.34) 20 (29.86) 
Black African 
American, n (%) 
20 (10.20) 14 (12.96) 2 (9.52) 4 (5.97) 
Hispanic or 
Latino, n (%)  
21 (10.71) 12 (11.11) 3 (14.29) 6 (8.96) 
Co-Morbidities     
Hypertension, n 
(%) 
128 (65.31) 73 (67.59) 13 (61.90) 42 (62.69) 
Diabetes, n (%) 48 (24.49) 30 (27.78) 8 (38.10) 10 (14.93) 
CHF, n (%) 84 (42.86) 44 (40.74) 14 (66.67) 26 (38.81) 
CVA, n (%) 55 (28.06) 33 (30.56) 5 (23.81) 17 (25.37) 
ESRD, n (%) 27 (13.78) 20 (18.52) 6 (28.57) 1 (1.49) 
COPD, n (%) 25 (12.76) 16 (14.81) 2 (9.52) 7 (10.45) 
Arrhythmia, n 
(%) 
39 (19.90) 26 (24.07) 3 (14.29) 10 (14.93) 
Affected Valve     
Aortic, n (%) 109 (55.61) 59 (54.63) 9 (42.86) 41 (61.19) 
Mitral, n (%) 135 (68.88) 70 (64.81) 16 (76.19) 49 (73.13) 
Tricuspid, n (%) 16 (8.16) 10 (9.26) 3 (14.29) 3 (4.48) 
Pre-Op Severity     
Fever, n (%) 135 (68.88) 71 (65.74) 15 (71.43) 49 (73.13) 
Angina, n (%) 27 (13.78) 15 (13.89) 5 (23.81) 7 (10.45) 
Abscess, n (%) 66 (33.67) 42 (38.89) 10 (47.62) 14 (20.90) 
Reoperation     
Prior Cardiac 
Surgeries, n (%) 
67 (34.18) 48 (44.44) 5 (23.81) 17 (25.37) 
Average STS 
Score 
6.73 7.97 9.20 4.18 
30 Day Post-Op 
Outcomes  
    
Mortality, n (%) 15 (7.65) 10 (9.26) 1 (4.76) 4 (5.97) 
Prosthetic Valve 
Dysfunction, n 
(%) 
2 (1.02) 2 (1.85) 0 (0.0) 0 (0.0) 
Septic Shock, n 
(%) 
30 (15.31) 17 (15.74) 3 (14.29) 10 (14.93) 
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Figure 8: Surgical Patient Data. The demographic, pre-operative, and post-operative 
outcomes collected for the surgical patients are represented in this figure. The total 
number of patients as well as the percentages in each category are reflected in this figure. 
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MI, n (%) 29 (14.80) 13 (12.04) 7 (33.33) 9 (13.43) 
Stroke, n (%) 10 (5.10) 5 (4.63) 1 (4.76) 4 (5.97) 
Embolic Events, 
n (%) 
32 (16.33) 18 (16.67) 2 (9.52) 12 (17.91) 
ARF/ESRD, n 
(%) 
40 (20.41) 25 (23.15) 6 (28.57) 9 (13.43) 
Infection, n (%) 39 (19.90) 24 (22.22) 7 (33.33) 8 (11.94) 
1 Year Post-Op 
Outcomes 
    
Mortality, n (%) 34 (17.35) 23 (21.30) 6 (28.57) 5 (7.46) 
Prosthetic Valve 
Dysfunction, n 
(%) 
10 (5.10) 6 (5.56) 2 (9.52) 2 (2.99) 
Septic Shock, n 
(%) 
34 (17.35) 20 (18.52) 4 (19.05) 10 (14.93) 
MI, n (%) 32 (16.33) 16 (14.81) 7 (33.33) 9 (13.43) 
  
Figure 8: Surgical Patient Data. The demographic, pre-operative, and post-operative 
outcomes collected for the surgical patients are represented in this figure. The total 
number of patients as well as the percentages in each category are reflected in this figure. 
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MEDICAL Overall (n=120) Staph (n=41) MRSA (n=35) Strep (n=44) 
Age 65.67 63.80 68.34 65.29 
Male, n (%) 67 (55.83) 20 (48.78) 15 (42.86) 32 (72.73) 
Female, n (%) 53 (44.17) 21 (51.22) 20 (57.14) 12 (27.27) 
White, n (%) 55 (45.45) 20 (46.51) 15 (42.86) 20 (45.45) 
Unknown, n (%)  47 (38.85) 16 (38.21) 13 (37.14) 18 (40.91) 
Black African 
American, n (%) 
17 (14.05) 5 (11.63) 7 (20.00) 5 (11.36) 
Hispanic or 
Latino, n (%)  
27 (22.31) 11 (25.58) 5 (14.29) 11 (25.00) 
Co-Morbidities     
Hypertension, n 
(%) 
69 (57.50) 25 (60.98) 24 (68.57) 20 (45.45) 
Diabetes, n (%) 46 (38.33) 18 (43.90) 17 (48.57) 11 (25.00) 
CHF, n (%) 32 (26.67) 13 (31.71) 10 (28.57) 9 (20.45) 
CVA, n (%) 16 (13.33) 3 (7.32) 7 (20.00) 6 (13.64) 
ESRD, n (%) 18 (15.00) 8 (19.51) 9 (25.71) 1 (2.27) 
COPD, n (%) 12 (10.00) 4 (9.76) 6 (17.14) 2 (4.55) 
Arrhythmia, n 
(%) 
29 (24.17) 6 (14.63) 11 (31.43) 12 (27.27) 
Affected Valve     
Aortic, n (%) 52 (43.33) 16 (39.02) 12 (34.29) 24 (54.55) 
Mitral, n (%) 69 (57.50) 25 (60.98) 23 (65.71) 21 (47.73) 
     
Pre-Op Severity     
Fever, n (%) 63 (52.50) 20 (48.78) 16 (45.71) 27 (61.36) 
Angina, n (%) 3 (2.50) 0 (0.00) 0 (0.0) 3 (6.82) 
Abscess, n (%) 8 (6.67) 4 (9.76) 2 (5.71) 2 (4.55) 
Reoperation     
Prior Cardiac 
Surgeries, n (%) 
34 (28.33) 8 (19.51) 7 (20.00) 19 (43.18) 
Average STS 
Score 
9.01 11.10 11.14 5.485 
30 Day Post-Op 
Outcomes  
    
Mortality, n (%) 35 (29.17) 14 (34.15) 16 (45.71) 5 (11.36) 
Prosthetic Valve 
Dysfunction, n 
(%) 
0 (0.00) 0 (0.00) 0 (0.0) 0 (0.0) 
Septic Shock, n 
(%) 
14 (11.67) 3 (7.32) 8 (22.86) 3 (6.82) 
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Figure 9: Medical Patient Data. The demographic, pre-operative, and post-operative 
outcomes collected for the medical patients are represented in this figure. The total 
number of patients as well as the percentages in each category are reflected in this figure. 
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MI, n (%) 4 (3.33) 2 (4.88) 1 (2.86) 1 (2.27) 
Stroke, n (%) 11 (9.17) 4 (9.76) 4 (11.43) 3 (6.82) 
Embolic Events, 
n (%) 
23 (19.17) 9 (21.95) 7 (20.00) 7 (15.91) 
ARF/ESRD, n 
(%) 
4 (3.33) 0 (0.00) 4 (11.43) 0 (0.0) 
Infection, n (%) 2 (1.67) 2 (4.88) 0 (0.0) 0 (0.0) 
1 Year Post-Op 
Outcomes 
    
Mortality, n (%) 56 (46.67) 21 (51.22) 26 (74.29) 9 (20.45) 
Prosthetic Valve 
Dysfunction, n 
(%) 
0 (0.00) 0 (0.00) 0 (0.0) 0 (0.0) 
Septic Shock, n 
(%) 
17 (14.17) 3 (7.32) 11 (31.43) 3 (6.82) 
MI, n (%) 4 (3.33) 2 (4.88) 1 (2.86) 1 (2.27) 
Stroke, n (%) 13 (10.83) 4 (9.76) 5 (14.29) 4 (9.09) 
Embolic Events, 
n (%) 
24 (20.00) 9 (21.95) 7 (20.00) 8 (18.18) 
ARF/ESRD, n 
(%) 
6 (5.00) 0 (0.00) 5 (14.29) 1 (2.27) 
Infection, n (%) 8 (6.67) 6 (14.63) 0 (0.0) 2 (4.55) 
 
 
Figure 9: Medical Patient Data. The demographic, pre-operative, and post-operative 
outcomes collected for the medical patients are represented in this figure. The total 
number of patients as well as the percentages in each category are reflected in this figure. 
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 The overall comparison for of surgical and medical patients is presented in Table 
10. T tests were conducted to determine if there was a significant difference between the 
two cohorts. The medical patients had a significantly higher preoperative prevalence of 
diabetes (p=0.005) while the surgical patients had higher preoperative instances of CHF 
(p=0.001) and CVA (p=0.0005). The surgical patients also presented with a higher 
severity of infection and had significantly higher rates of preoperative fever (p=0.002), 
angina (p=0.00004), and valvular abscess (p<0.5). Overall, the STS score for the medical 
patients was an average of 9.01 which was significantly higher than the 6.73 of surgical 
patients (p=0.017). Surgical patients also had a higher percentage of prior cardiac 
surgeries, but this number was not significantly different that the medical patients.  
 Postoperatively, medical patients exhibited a significantly higher rate of mortality 
at both 30 days and 1 year post-op (p<0.05).  However, surgical patients presented with 
significantly higher rates of MI, ARF, and recurrence of infection at both 30 days and 1 
year (p<0.05). 
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 Surgical (n=196) Medical (n=120) P value 
Age 58.07 65.67  
Male, n (%) 126 (63.64) 67 (55.83)  
Female, n (%) 70 (36.36) 53 (44.17)  
Co-Morbidities    
Hypertension, n (%) 128 (65.31) 69 (57.50) 0.085 
Diabetes, n (%) 48 (24.49) 46 (38.33) 0.005 
CHF, n (%) 84 (42.86) 32 (26.67) 0.001 
CVA, n (%) 55 (28.06) 16 (13.33) 0.0005 
ESRD, n (%) 27 (13.78) 18 (15.00) 0.382 
COPD, n (%) 25 (12.76) 12 (10.00) 0.225 
Arrhythmia, n (%) 39 (19.90) 29 (24.17) 0.190 
Affected Valve    
Aortic, n (%) 109 (55.61) 52 (43.33)  
Mitral, n (%) 135 (68.88) 69 (57.50)  
Tricuspid, n (%) 16 (8.16)   
Pre-Op Severity    
Fever, n (%) 135 (68.88) 63 (52.50) 0.002 
Angina, n (%) 27 (13.78) 3 (2.50) 0.00004 
Abscess, n (%) 66 (33.67) 8 (6.67) 0.0000000006 
Reoperation    
Prior Cardiac 
Surgeries, n (%) 
67 (34.18) 34 (28.33) 0.137 
Average STS Score 6.73 9.01 0.017 
30 Day Post-Op 
Outcomes  
   
Mortality, n (%) 15 (7.65) 35 (29.17) 0.000002 
Prosthetic Valve 
Dysfunction, n (%) 
2 (1.02) 0 (0.00) 0.079 
Septic Shock, n (%) 30 (15.31) 14 (11.67) 0.177 
MI, n (%) 29 (14.80) 4 (3.33) 0.00009 
Stroke, n (%) 10 (5.10) 11 (9.17) 0.094 
Embolic Events, n 
(%) 
32 (16.33) 23 (19.17) 0.263 
ARF/ESRD, n (%) 40 (20.41) 4 (3.33) 0.0000002 
Infection, n (%) 39 (19.90) 2 (1.67) 0.00000005 
1 Year Post-Op 
Outcomes 
   
Mortality, n (%) 34 (17.35) 56 (46.67) 0.00000005 
Prosthetic Valve 
Dysfunction, n (%) 
10 (5.10) 0 (0.00) 0.0007 
Septic Shock, n (%) 34 (17.35) 17 (14.17) 0.224 
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MI, n (%) 32 (16.33) 4 (3.33) 0.00002 
Stroke, n (%) 30 (15.31) 13 (10.83) 0.122 
Embolic Events, n 
(%) 
39 (19.90) 24 (20.00) 0.491 
ARF/ESRD, n (%) 46 (23.47) 6 (5.00) 0.000003 
Infection, n (%) 55 (28.06) 8 (6.67) 0.0000005 
 
Figure 10: Surgical vs. Medical Patient Data Comparison. The demographic, pre-
operative, and post-operative outcomes collected for the medical patients are represented 
in this figure. The total number of patients as well as the percentages in each category are 
reflected in this figure. 
 
 
 The surgical and medical cohorts were then further subdivided by invading 
pathogen to analyze the pre and post treatment comorbidities and outcomes. The 
Streptococcus subdivision yielded sixty seven (67) surgical patients with an average age 
of 56.19 and forty four (44) medical patients with an average age of 65.29. Medical 
patients exhibited significantly higher rates or preoperative arrhythmia and surgical 
patients exhibited higher rates of preoperative hypertension, CHF, and abscess (p<0.05). 
Although the average STS score was higher for medical patients than surgical patients, it 
was not statistically significant. At 30 days, there was no statistically significant 
difference in mortality, however, there was a much higher rate of MI in the surgical 
cohort (p=0.010). At 1 year post-treatment, medical patients had a significantly higher 
mortality rate (p=0.032) despite surgical patients exhibited higher rates of MI, ESRD, and 
recurrence of infection.  
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 Strep Surgical 
(n=67) 
Strep Medical 
(n=44) 
P value 
Age 56.19 65.29  
Male, n (%) 48 (71.64) 32 (72.73)  
Female, n (%) 19 (28.36) 12 (27.27)  
Co-Morbidities    
Hypertension, n (%) 42 (62.69) 20 (45.45) 0.039 
Diabetes, n (%) 10 (14.93) 11 (25.00) 0.103 
CHF, n (%) 26 (38.81) 9 (20.45) 0.018 
CVA, n (%) 17 (25.37) 6 (13.64) 0.060 
ESRD, n (%) 1 (1.49) 1 (2.27) 0.387 
COPD, n (%) 7 (10.45) 2 (4.55) 0.117 
Arrhythmia, n (%) 10 (14.93) 12 (27.27) 0.040 
Affected Valve    
Aortic, n (%) 41 (61.19) 24 (54.55)  
Mitral, n (%) 49 (73.13) 21 (47.73)  
Tricuspid, n (%) 3 (4.48)   
Pre-Op Severity    
Fever, n (%) 49 (73.13) 27 (61.36) 0.102 
Angina, n (%) 7 (10.45) 3 (6.82) 0.251 
Abscess, n (%) 14 (20.90) 2 (4.55) 0.003 
Reoperation    
Prior Cardiac 
Surgeries, n (%) 
17 (25.37) 19 (43.18) 0.135 
Average STS Score 4.18 5.485 0.06 
30 Day Post-Op 
Outcomes  
   
Mortality, n (%) 4 (5.97) 5 (11.36) 0.171 
Prosthetic Valve 
Dysfunction, n (%) 
0 (0.0) 0 (0.0)  
Septic Shock, n (%) 10 (14.93) 3 (6.82) 0.083 
MI, n (%) 9 (13.43) 1 (2.27) 0.010 
Stroke, n (%) 4 (5.97) 3 (6.82) 0.430 
Embolic Events, n 
(%) 
12 (17.91) 7 (15.91) 0.392 
ARF/ESRD, n (%) 9 (13.43) 0 (0.0) 0.001 
Infection, n (%) 8 (11.94) 0 (0.0) 0.002 
1 Year Post-Op 
Outcomes 
   
Mortality, n (%) 5 (7.46) 9 (20.45) 0.032 
Prosthetic Valve 
Dysfunction, n (%) 
2 (2.99) 0 (0.0) 0.079 
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Septic Shock, n (%) 10 (14.93) 3 (6.82) 0.084 
MI, n (%) 9 (13.43) 1 (2.27) 0.010 
Stroke, n (%) 8 (11.94) 4 (9.09) 0.315 
Embolic Events, n 
(%) 
13 (19.40) 8 (18.18) 0.437 
ARF/ESRD, n (%) 10 (14.93) 1 (2.27) 0.006 
Infection, n (%) 10 (20.41) 2 (4.55) 0.029 
 
Figure 11: Streptococci Surgical vs. Medical Patient Data. The demographic, pre-
operative, and post-operative outcomes collected for the Streptococci surgical and 
medical patients are represented in this figure. The total number of patients as well as the 
percentages in each category are reflected in this figure. 
 
 
The Staphylococcus subdivision yielded one hundred eight (108) surgical patients 
with an average age of 58.67 and forty one (41) medical patients with an average age of 
63.80. Medical patients exhibited significantly higher rates or preoperative diabetes 
(p=0.038) and surgical patients exhibited higher rates of preoperative CVA (p=0.0001), 
prior cardiac surgery (p=0.001), fever (p=0.034), angina (p<0.05) and abscess (p<0.05). 
At 30 days, medical patients had a significantly higher rate of mortality (p=0.001) 
although surgical patient had significantly higher rates of ESRD (p<0.05) and recurrence 
of infection (p<0.05). At 1 year, the disparities increase significantly. Medical patients 
had significantly higher rates of mortality (p<0.05) but surgical patients experienced 
higher rates of septic shock, MI, ESRD, and recurrence of infection (p<0.05). 
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 Staph (n=108) Staph Medical 
(n=41) 
P value 
Age 58.67 63.80  
Male, n (%) 63 (58.33) 20 (48.78)  
Female, n (%) 45 (41.67) 21 (51.22)  
Co-Morbidities    
Hypertension, n (%) 73 (67.59) 25 (60.98) 0.159 
Diabetes, n (%) 30 (27.78) 18 (43.90) 0.038 
CHF, n (%) 44 (40.74) 13 (31.71) 0.153 
CVA, n (%) 33 (30.56) 3 (7.32) 0.0001 
ESRD, n (%) 20 (18.52) 8 (19.51) 0.446 
COPD, n (%) 16 (14.81) 4 (9.76) 0.193 
Arrhythmia, n (%) 26 (24.07) 6 (14.63) 0.089 
Affected Valve    
Aortic, n (%) 59 (54.63) 16 (39.02)  
Mitral, n (%) 70 (64.81) 25 (60.98)  
Tricuspid, n (%) 10 (9.26)   
Pre-Op Severity    
Fever, n (%) 71 (65.74) 20 (48.78) 0.034 
Angina, n (%) 15 (13.89) 0 (0.00) 0.00003 
Abscess, n (%) 42 (38.89) 4 (9.76) 0.00001 
Reoperation    
Prior Cardiac 
Surgeries, n (%) 
48 (44.44) 8 (19.51) 0.001 
Average STS Score 7.97 11.10 0.078 
30 Day Post-Op 
Outcomes  
   
Mortality, n (%) 10 (9.26) 14 (34.15) 0.001 
Prosthetic Valve 
Dysfunction, n (%) 
2 (1.85) 0 (0.00) 0.079 
Septic Shock, n (%) 17 (15.74) 3 (7.32) 0.062 
MI, n (%) 13 (12.04) 2 (4.88) 0.063 
Stroke, n (%) 5 (4.63) 4 (9.76) 0.160 
Embolic Events, n 
(%) 
18 (16.67) 9 (21.95) 0.240 
ARF/ESRD, n (%) 25 (23.15) 0 (0.00) 0.0000001 
Infection, n (%) 24 (22.22) 2 (4.88) 0.0006 
1 Year Post-Op 
Outcomes 
   
Mortality, n (%) 23 (21.30) 21 (51.22) 0.0005 
Prosthetic Valve 
Dysfunction, n (%) 
6 (5.56) 0 (0.00) 0.006 
Septic Shock, n (%) 20 (18.52) 3 (7.32) 0.023 
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MI, n (%) 16 (14.81) 2 (4.88) 0.021 
Stroke, n (%) 17 (15.74) 4 (9.76) 0.155 
Embolic Events, n 
(%) 
22 (20.37) 9 (21.95) 0.418 
ARF/ESRD, n (%) 29 (26.85) 0 (0.00) 0.0000004 
Infection, n (%) 36 (33.33) 6 (14.63) 0.0055 
 
Figure 12: Staphylococci Surgical vs. Medical Patient Data. The demographic, pre-
operative, and post-operative outcomes collected for the Streptococci surgical and 
medical patients are represented in this figure. The total number of patients as well as the 
percentages in each category are reflected in this figure. 
 
 
The MRSA subdivision yielded twenty one (21) surgical patients with an average 
age of 61.03 and thirty five (35) medical patients with an average age of 68.34. Surgical 
patients exhibited significantly higher rates or preoperative CHF, fever, angina and 
abscess. At both 30 days and 1year, medical patients had significantly higher rates of 
mortality (p<0.05) and surgical patients had significantly higher rates of recurrence of 
infection (p<0.05). 
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 MRSA (n=21) MRSA Medical 
(n=35) 
P value 
Age 61.03 68.34  
Male, n (%) 15 (71.43) 15 (42.86)  
Female, n (%) 6 (28.57) 20 (57.14)  
Co-Morbidities    
Hypertension, n (%) 13 (61.90) 24 (68.57) 0.438 
Diabetes, n (%) 8 (38.10) 17 (48.57) 0.186 
CHF, n (%) 14 (66.67) 10 (28.57) 0.005 
CVA, n (%) 5 (23.81) 7 (20.00) 0.310 
ESRD, n (%) 6 (28.57) 9 (25.71) 0.315 
COPD, n (%) 2 (9.52) 6 (17.14) 0.187 
Arrhythmia, n (%) 3 (14.29) 11 (31.43) 0.055 
Affected Valve    
Aortic, n (%) 9 (42.86) 12 (34.29)  
Mitral, n (%) 16 (76.19) 23 (65.71)  
Tricuspid, n (%) 3 (14.29)   
Pre-Op Severity    
Fever, n (%) 15 (71.43) 16 (45.71) 0.048 
Angina, n (%) 5 (23.81) 0 (0.0) 0.005 
Abscess, n (%) 10 (47.62) 2 (5.71) 0.001 
Reoperation    
Prior Cardiac 
Surgeries, n (%) 
5 (23.81) 7 (20.00) 0.063 
Average STS Score 9.20 11.14 0.118 
30 Day Post-Op 
Outcomes  
   
Mortality, n (%) 1 (4.76) 16 (45.71) 0.0004 
Prosthetic Valve 
Dysfunction, n (%) 
0 (0.0) 0 (0.0)  
Septic Shock, n (%) 3 (14.29) 8 (22.86) 0.189 
MI, n (%) 7 (33.33) 1 (2.86) 0.006 
Stroke, n (%) 1 (4.76) 4 (11.43) 0.168 
Embolic Events, n 
(%) 
2 (9.52) 7 (20.00) 0.122 
ARF/ESRD, n (%) 6 (28.57) 4 (11.43) 0.082 
Infection, n (%) 7 (33.33) 0 (0.0) 0.003 
1 Year Post-Op 
Outcomes 
   
Mortality, n (%) 6 (28.57) 26 (74.29) 0.0002 
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Prosthetic Valve 
Dysfunction, n (%) 
2 (9.52) 0 (0.0) 0.081 
Septic Shock, n (%) 4 (19.05) 11 (31.43) 0.129 
MI, n (%) 7 (33.33) 1 (2.86) 0.006 
Stroke, n (%) 5 (23.81) 5 (14.29) 0.222 
Embolic Events, n 
(%) 
4 (19.05) 7 (20.00) 0.434 
ARF/ESRD, n (%) 7 (33.33) 5 (14.29) 0.073 
Infection, n (%) 9 (42.86) 0 (0.0) 0.0005 
 
  
Figure 13: MRSA Surgical vs. Medical Patient Data. The demographic, pre-operative, 
and post-operative outcomes collected for the MRSA surgical and medical patients are 
represented in this figure. The total number of patients as well as the percentages in each 
category are reflected in this figure. 
 
 
 
Procedure Number of Patients, (%) 
MVR 65, (33.16) 
AVR 48, (24.49) 
AVR/MVR 30, (15.31) 
ARR 12, (6.12) 
MVr 11, (5.61) 
MVR/CABG 10, (5.10) 
AVR/CABG 6, (3.06) 
 
Figure 14: Surgical Procedures. The most popular procedures that were performed for 
IE. Other procedures also included Aortic Valve Repair (AVr), AVR/MVR/Coronary 
Artery Bypass Graft (CABG), and ARR/CABG. 
 
 In Figure 14, the most common surgical interventions are listed. Single or 
multiple valve replacement procedures were more prevalent than valve repair procedures, 
aortic root replacements, and procedures involving CABG. 33.16% of patients received 
 35 
an MVR, 24.49% of patients received and AVR and 15.31% of patients received both an 
MVR and AVR. 
 
Figure 15: 30 Day Surgical Cox Regression. A Cox Regression Analysis was 
conducted to control for pre-therapy comorbidities and demographics and predict the 
likelihood of mortality based on the patient’s preoperative patient characteristics. The 
results for the surgical cohort of patients at 30 Days is represented here. 
 
Figure 15 displays the results of the Cox Regression analysis performed at 30 
Days for the patients in the surgical cohort. There was no variable that returned 
significant in this analysis.  
Figure 16 displays the results of the Cox Regression analysis performed at 1 year 
for the patients in the surgical cohort. Age (p=0.049), HTN (p=0.016), and ESRD 
(p=0.019) proved to be significant predictors of mortality. As age increases by 1 year 
(HR: 1.033, 1.000-1.066 95% CI, p=0.049), there is an increase in risk in experiencing 
mortality. Similarly, as patients are diagnosed with ESRD (HR: 3.561; 1.235-10.267 95% 
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CI, p=0.019), the risk of mortality from IE increases. Conversely, as patients are 
diagnosed with HTN (HR: 0.318, .126-.805 95% CI, p=0.016) the risk of mortality from 
IE decreases at 1 year. 
 
Figure 16: 1 Year Surgical Cox Regression. A Cox Regression Analysis was conducted 
to control for pre-therapy comorbidities and demographics and predict the likelihood of 
mortality based on the patient’s preoperative patient characteristics. The results for the 
surgical cohort of patients at 1 year is represented here. 
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Figure 17: 30 Day Medical Cox Regression. A Cox Regression Analysis was conducted 
to control for pre-therapy comorbidities and demographics and predict the likelihood of 
mortality based on the patient’s preoperative patient characteristics. The results for the 
medical cohort of patients at 30 Days is represented here. 
 
 
Figure 17 displays the results of the Cox Regression analysis performed at 30 
Days for the patients in the medical cohort. The only significant result from this analysis 
was that the presence of valvular abscess (HR: 3.151, 1.128-8.806 95% CI, p=0.029) 
increases the risk of mortality at 30 Days. All other variables had no effect on mortality at 
30 Days in the medical patients.  
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Figure 18: 1 Year Medical Cox Regression. A Cox Regression Analysis was conducted 
to control for pre-therapy comorbidities and demographics and predict the likelihood of 
mortality based on the patient’s preoperative patient characteristics. The results for the 
medical cohort of patients at 1 Year is represented here. 
 
 
Figure 18 displays the results of the Cox Regression analysis performed at 1 Year 
for the patients in the medical cohort. The only significant result from this analysis was 
that the presence of fever (HR: 0.516, 0.288-0.924 95% CI, p=0.026) decreases the risk 
of mortality at 1 year. All other variables had no effect on mortality at 30 Days in the 
medical patients.  
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Figure 19: Kaplan Meier Curve for 30 Day and 1 Year Comparisons. A Kaplan 
Meier Analysis was conducted to graph the survival of the surgical and medical patients 
at both 30 days and 1 year 
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 Figure 19 graphically portrays the mortality amongst the surgical and medical 
cohorts at both 30 days and 1 year. The p value is <0.05 for this graph and confirms the 
significance that was first calculated in the T tests.  
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DISCUSSION 
  
Staphylococcus, MRSA, and Streptococcus are the major causative organisms of 
IE. IE is a serious disease with a complicated prognosis and involves a clinical course 
that offers opportunities for medical management and surgical intervention. Clinicians 
weigh the severity of the infection and the surgical risk when deciding which option is 
the best fit for their patients. Known outcomes of medical management and surgical 
intervention greatly assist the clinician in making their ultimate decision. In this study, 
perioperative and 1 year mortality for treatment of IE was significantly higher in the 
medical cohort than the surgical population once all 3 subgroups were analyzed together. 
When analyzed separately, the Staphylococcus and MRSA group continued to show that 
medical management leads to significantly higher mortality rates at 30 days and 1 year 
while the Streptococcus group presented significance only at 1 year.  
IE is a very rare disease that affects less than 1% of the population, but once 
contracted, it holds a 1-year mortality rate of 40%. It is thus important to gather data that 
examine and compare patients treated medically and surgically in order to determine the 
extent of post-treatment complications.   As expected, the surgical cohort displayed significantly higher preoperative 
comorbidities than the medical cohort. Significantly higher rates of CHF and preoperative 
CVA were observed. Though not significant, the surgical cohort had higher rates of 
COPD, hypertension, and prior cardiac surgery as well. Furthermore, surgical patients 
showed significantly higher rates of preoperative fever, angina, and abscess. The 
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combination of these factors places the surgical patients in a more severe category of IE 
infection than the medical patients. Despite evidence that surgical patients had a more 
severe case of infection, they had a significantly lower STS score. This can be attributed 
to the higher overall age of the medical patients and the higher proportion of females in 
the medical cohort- which both contribute to higher STS scores for similar procedures. 
Additionally, since STS cannot account for multiple valve procedures occurring 
concurrently, the surgical STS scores may be lower than the actual surgical risk involved 
in receiving multiple valve replacements.  
Based on prior studies, patients diagnosed with left sided IE have more severe 
preoperative symptoms than those with right sided IE (Musci et al., 2007). Since the 
more severely infected patients with IE are operated on, we predicted that the surgical 
patients would also present with a complicated post-operative course (Byrne et al., 2011). 
Our data showed that surgical patients did experience significantly higher rates of MI, 
ESRD, and recurrence of infection at both 30 days and 1 year post-operatively. However, 
our data shows that medical patients had a significantly higher mortality rate at both 30 
days and 1 years post-operatively.  
This is an interesting finding because even though the surgical patients have 
significantly higher rates of post-operative complications, those complications can be 
managed without mortality, which provides evidence that surgical valve replacement may 
be superior to medical management. The medical patients succumb to their IE and 
experience mortality at a much higher rate, showing that IE is very severe and shows a 
rapid clinical course.  
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Most of the secondary outcomes of the study were experienced within 30 days in 
both the cohorts. For example, thirty (30) surgical patients exhibited septic shock in the 
first 30 days but only four (4) experienced septic shock between 30 days and 1 year. This 
trend is seen again in the surgical population when twenty nine (29) patients experienced 
an MI in the first 30 days and only three (3) experienced an MI between 30 days and 1 
year. In the medical cohort, a similar pattern emerges where in the first 30 days fourteen 
(14) patients experience septic shock and only three (3) experience septic shock between 
30 days and 1 year. This keys in on the importance of the first 30 days post-treatment. If 
patients are closely monitored post-operatively and post medical therapy, there is a very 
high likelihood that they will not experience adverse clinical outcomes within the next 11 
months. An important distinction to be made is that this trend is not true for all post-
treatment outcomes. The occurrence of stroke in surgical patients is very high between 30 
days and 1 year. At 30 days, only ten (10) surgical patients presented with stroke but 
between 30 days and 1 year, twenty (20) new patients presented with stroke, which is 
clinically concerning. Surgical IE patients will need to be closely monitored for the 
presentation of stroke post-operatively and be treated accordingly. Clinicians are aware of 
these developments and preventative measures have also been considered (Thuny, 2005).    
The Cox Regression Analysis conducted at 1 year post-operatively for the 
surgical cohort showed that age and pre-operative ESRD contribute to an increase risk of 
mortality. This was expected as increasing age adds significant risk to the long term 
outcomes of surgical patients due to the increased operative risk. ESRD has also been 
shown to lead to deleterious outcomes in patients contracting IE and needing valve 
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replacement surgery (Rekik et al., 2009). Additionally, our analysis returned showing that 
patients with hypertension had a decreased risk of mortality post-operatively. This was 
unexpected as preoperative hypertension is a severe medical condition and is worth 
examining further to determine if in fact there is a significant effect of IE patients.   
Our Cox Regression Analysis for medical patients at 30 days showed that patients 
with a valvular abscess are at a significant risk of mortality. Our data and prior research 
suggests that the presence of a valvular abscess in IE cases is severe and should urgently 
be treated (Knosalla, 2000). This increase in risk that was found in our data paired with 
the high mortality rate for patients in the medical cohort, suggests that patients presenting 
with valvular abscess should be treated surgically for a valve replacement. Of the eight 
(8) medical patients presenting with a valvular abscess, five (5) passed away within 30 
days and six (6) passed away within 1 year. Following valve replacement surgery only 
three (3) of the sixty six (66) surgical patients passed away within 30 days and ten (10) 
passed away within 1 year, which is a significant difference. This grim prognosis of 
medically treated patients suggests that any future patient presenting with left sided 
valvular abscess for IE be treated surgically instead of with antibiotics.   
The high risk of operative mortality is often considered as the main reason to not 
operate on a patient. Many IE patients are consulted for surgery and the decision is 
ultimately made to not operate and treat medically based on this risk. In our surgical 
cohort, we had fifty four (54) surgical patients who presented with an STS score above 8, 
deeming them high risk. Out of those fifty four (54) patients, six (6) died (11.11%) within 
the first 30 days and (sixteen) 16 died (29.63%) within 1 year. In our medical cohort, we 
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had forty two (42) patients presenting with a high risk STS score. Fourteen (14) died 
(33.33%) within 30 days and twenty two (22) died (52.38%) within 1 year. This data will 
aid clinicians and surgeons in the future in determining if they should operate on 
traditionally high risk patients. The difference in mortality between the high risk surgical 
and medical patients is significant and offers concrete data as to why it may benefit 
patients with left-sided IE to undergo valve replacement surgery.  
MRSA patients presented with the highest STS scores for both the surgical and 
medical cohorts. Despite this high operative risk, at 30 days it presented with the lowest 
rate of surgical mortality (4.76% for MRSA compared to 5.97% for Streptococcus and 
9.26% for Staphylococcus). The 30 day medical mortality rate was 45.71% for MRSA, 
11.36% for Streptococcus, and 34.15% for Staphylococcus, which are all higher than the 
pathogen specific surgical mortality rate at 30 days. Although all pathogen specific 
mortality rates are higher, the MRSA and Staphylococcus differences were statistically 
significant. This distinction endorses MRSA and Staphylococcus IE as being more severe 
compared to Streptococcal infection. Prior studies have suggested this notion and our 
study provides further evidence to support that claim (Han et al., 2017).  
The 1 year mortality data in each of these cohorts follows a similar trend and is 
significant across all 3 pathogens. 28.57% of surgical MRSA patients died compared to 
74.29% of medical MRSA patients, 7.46% of surgical Streptococcal patients died 
compared to 20.45% of medical Streptococcal patients, and 21.30% of surgical 
Staphylococcal patients died compared to 51.22% of Staphylococcal medical patients. 
The higher rates of mortality between the three most commonly occurring pathogens 
 46 
found in IE can be used as a potential reference for future cases of IE with other 
pathogens. Based on our data, more studies on different pathogens can be conducted to 
determine if this trend is consistent.  
As mentioned earlier, negative post-treatment surgical outcomes were 
significantly higher than the negative post-treatment medical outcomes. The most 
noteworthy trend this data showed is the recurrence of infection in surgical patients. All 
pathogen specific surgical patients exhibited significantly higher rates of recurrence of 
infection at 30 days and 1 year. This demonstrates that although surgery is effective in 
preventing mortality at 30 days and 1 year, there is concern for reinfection and potential 
recurrence of IE. Despite these high numbers of recurrence clinicians are able to still 
keep mortality rates significantly lower for surgical patients, which further suggests that 
once the initial pervasive infection is treated, any secondary infection can be slowed. 
Seven (7) surgical MRSA patients experienced recurrence of infection at 30 days and 
only two (2) experienced between 30 days and 1 year. In the Streptococcal population, 
eight (8) patients presented with infection within 30 days post-operatively and two (2) 
presented with infection between 30 days and 1 year. This keys in on the importance of 
immediate post-operative monitoring of infection and the certainty that all of the 
vegetation was removed during the operation. In the medical cohort, zero (0) MRSA 
patients presented with recurrence of infection at 30 days and 1 year and only two (2) 
Streptococcal patients presented with infection recurrence within 1 year. This suggests 
that long term antibiotic therapy is effective at clearing the infection, but may not act 
quick enough to prevent other complications such as stroke, embolic events, or septic 
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shock from causing mortality. This is an important distinction that this study wishes to 
emphasize. Surgical intervention is more efficacious in preventing mortality in left sided 
IE patients. Medical therapy is effective in clearing the infection over the course of the 
regiment. Patients in the medical cohort were prescribed various combinations of 
vancomycin, gentamicin, penicillin, oxacillin, ceftriaxone, and rifampin for an average of 
5 weeks. Thirty five (35) patients (29.17%) in the medical cohort perished within 30 days 
and before the full course of antibiotics could be completed. As mentioned in the 
methods section, the 30 day window was started once there was a positive blood culture 
and a definitive vegetation confirmed by TEE or TTE. Based off of our results, these 
patients may have benefitted by surgical intervention and valve replacement instead of 
medical therapy.  
Our study is not without major limitations. Since this was a retrospective analysis, 
we were limited in how much data we could collect from chart review. Many patients 
from the initial 1210 had to be excluded due to lack of follow up, inconclusive diagnosis 
of definite IE, and lack of preoperative characteristics and baseline data. This study could 
be much stronger if our sample size was larger and included patients with more robust 
data. Our decision to include only patients diagnosed with MRSA IE, Streptococcal IE, 
and Staphylococcal IE may be viewed as a limitation, but we believe that it is more 
pertinent to address the most common pathogens and how they are treated medically and 
surgically rather than include a wide range of pathogens with different responses to 
medical therapy. The definition and categorization of patients in the medical cohort can 
be viewed as another limitation. It was difficult to decide on how the 30 day and 1 year 
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window would be defined for the medical patients. Many patients were started on 
antibiotic therapy when they presented with bacteremia prophylactically before there was 
a positive TTE or TEE confirming valvular IE. We decided to make the start date or 
operative date on these patients as the first day that they presented with a positive TTE or 
TEE for valvular IE as that would be the first day that valve replacement would be 
considered as an option. We understand the difficulty in assessing the efficacy of medical 
management based on this decision, but remained consistent throughout our analysis and 
present the data with full transparency as to our rationale and logic surrounding this 
determination. Additionally, our institution is a high volume referral hospital where very 
severely ill patients are referred for treatment. The severity of IE in this population may 
be higher than the severity in other institutions and should be factored in to the 
interpretation of data. Even with this increase in severity, the surgical patients still 
outperformed the medical patients in survival at 30 days and 1 year after addressing the 
surgical risk and preoperative severity of infection. To our understanding, this study 
offers a comprehensive view of surgically and medically treated IE patients with a full 
evaluation of post-treatment outcomes.  
This significant difference in mortality, coupled with the performance of high risk 
surgical patients and the fact that the surgical patients all had higher rates of preoperative 
fever, angina, and valvular abscess, provides strong evidence to the benefit of surgical 
intervention compared to medical management for treatment of left sided IE. The first 30 
days post-treatment for IE, as highlighted above, is key in maintaining and controlling the 
disease. Surgical intervention, even with its drawbacks with post-operative complications 
 49 
of septic shock, stroke, and MI, offers an immediate eradication of the disease and a 
method of decreasing the mortality rate in the population. Future studies should be 
conducted on this topic to confirm our observations and determine if a trend in the data 
can be corroborated.          
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